Relationship Between the Type of BCR-ABL Rearrangement and Bone Marrow Histopathological Features in Chronic Myeloid Leukemia

References

• Champlin R E, Golde D W. Chronic myelogenous leukemia: recent, advances. Blood 1985; 65: 1039–47
   PubMed Web of Science ®Google Scholar
• de Klein A, van Kessel A G, Grosveld G, et al. A celullar oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 755–67
   PubMedGoogle Scholar
• Bartra M C R, de Klein A, Hagemeijer A, et al. Translocation of c-abl oneogene correlates with the presence of Philadelphia chromosome in chronic myeloid leukemia. Nature 1983; 306: 277–80
   PubMedGoogle Scholar
• Heisterkamp N, Stephenson J R, Groffent J, et al. Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukemia. Nature 1983; 306: 239–42
   PubMed Web of Science ®Google Scholar
• Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the ber gene and its role in the Ph' translocation. Nature 1985; 315: 758–61
   PubMed Web of Science ®Google Scholar
• Ben-Neriah Y, Daley G Q, Mes-Masson A M, Witte O N, Baltimore D. The chronic myelogenous leukemia specific p210 protein is the product of ber-abl hybrid gene. Science 1986; 233: 212–4
   PubMed Web of Science ®Google Scholar
• Morgan G J, Hernandez A, Chan L C, Hughs T, Martiat P, Weidemann L M. The role of alternative splicing patterns of BCR/ABL transcripts in the generation of blast crisis of chronic myeloid leukemia. Br J Haematol 1990; 76: 33–8
   PubMed Web of Science ®Google Scholar
• Mills K I, Sproul A M, Leibowitz D, Burnett A K. Mapping of breakpoints, and relationship to BCR-ABL RNA expression, in Philadelphia chromosome-positive chronic myeloid leukaemia patients with a breakpoint around exon 14(b3) of BCR gene. Leukemia 1991; 59: 937–41
   Google Scholar
• Zaccaria A, Martinelli G, Buzzi M, et al. The type of BCR/ABL junction does not predict the survival of atients with Ph1-positive chronic myeloid leukemia. Br J Haematol 1993; 84: 265–8
   PubMed Web of Science ®Google Scholar
• Zaccaria A, Martinelli G, Buzzi M, Farabegoli P. Molecular biology contribute to refine prognosis ans to select treatment?. Leuk lymphoma 1993; 11: 81–9
   PubMed Web of Science ®Google Scholar
• Dreazen O, Berman M, Gale R P. Molecular abnormalities of BCR and c-ABL in chronic myelogenous leukemia associated with long chronic phase. Blood 1988; 71: 797–9
   PubMed Web of Science ®Google Scholar
• Tanaka K, Hashimoto T, Oguma N, Dohy H, Kamada N. Influence of M-BCR breakpoint sites on duration of chronic phase in 100 patients with chronic myelocytic leukemia. Cancer Genet Cytogenet 1993; 70: 39–47
   PubMed Web of Science ®Google Scholar
• Bettini R, Ferrari V, Rapazzini P. Bone marrow patterns and survival in chronic myeloid leukemia. Haematologica (Paiva) 1985; 70: 272–3
   PubMedGoogle Scholar
• Frisch B, Bartl R, Burkhardt R, Jager K, Mahal G, Kettn'er G. Classification of myeloproliferative disorders by bone marrow histology. Bibliotheca Haemat 1984; 50: 57–80
   Google Scholar
• Lorand-Metze I. Bone marrow morphology at diagnosis as a prognostic parameter in Philadelphia-positive chronic myelogenous leukaemia (CML). Br J Haematol 1989; 71: 163
   PubMed Web of Science ®Google Scholar
• Buhr T, Choritz H, Georgii A. The impact of megakaryocyte proliferation for evolution of myelofibrosis. Virchows Archiv A. Pathol Anat 1992; 420: 473–8
   Google Scholar
• Georgii A, Vykoupil K F, Buhr T, et al. Chronic myeloproliferative disorders in bone marrow biopsies. Pathol Res Pract 1990; 186: 3–27
   PubMed Web of Science ®Google Scholar
• Inokuchi K, Inoue T, Arinobu T, et al. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood 1991; 78: 8195–7
   Google Scholar
• Inokuchi K, Nomura T. The relationship between the type of bcr-abl hybrid messenger RNA and thrombopoiesis in Philadelphia-positive chronic myelogenous leukemia. Leuk Lymph. 1993; 10: 9–15
   PubMed Web of Science ®Google Scholar
• Shepherd P C A, Bond C, Allan N C. Molecular breakpoints and platelet counts in chronic myeloid leukemia. Blood 1992; 80: 556–63
   PubMed Web of Science ®Google Scholar
• Opalka B, Wandl U B, Kloke O, Beer U, Seeber S, Niederle N. No correlation between site of breakpoint in the BCR gene and platelets counts in Philadelphia chromosome-positive CML. Leukemia Res 1992; 16: 937–9
   PubMed Web of Science ®Google Scholar
• Opalka B, Wandl U B, Stutenkemper R, Kloke O, Seeber S, Niederle N. No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemia. Blood 1992; 80: 1854–8
   PubMedGoogle Scholar
• Seabright M A. A rapid banding technique for human chromosomes. Lancet 1971; 2: 971–2
   PubMed Web of Science ®Google Scholar
• Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium Thiocyanate-Phenol-Chloroform extraction. Ann Biochem 1987; 162: 156–9
   Web of Science ®Google Scholar
• Roth M S, Antin J H, Bingham E L, Ginsburg D. Detection of Philadelphia, chromosome-positive, cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia. Blood 1989; 74: 882–5
   PubMed Web of Science ®Google Scholar
• Siegel S. Estadistica non paramétrica. Trillas, Mexico 1975; 356
   Google Scholar